 |
0 Diseases |  |
4 Trials |
|
4 Trials |  |
17 News |  |
| «12 |
- ||| lanraplenib (GS-9876) / Gilead, Galapagos, Kronos Bio
Enrollment closed, Trial primary completion date: Safety, Tolerability, and Efficacy of GS-9876 in Participants With Active Rheumatoid Arthritis on Background Therapy With Methotrexate (clinicaltrials.gov) - Jun 19, 2017
P2, N=83, Active, not recruiting, Sponsor: Gilead Sciences
Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2018 --> Aug 2017
- | lanraplenib (GS-9876) / Gilead, Galapagos, Kronos Bio, Jyseleca (filgotinib) / Galapagos, Gilead, SOBI
Enrollment open: Study to Evaluate Safety and Efficacy of Filgotinib and Lanraplenib in Females With Moderately-to-Severely Active Cutaneous Lupus Erythematosus (CLE) (clinicaltrials.gov) - May 31, 2017
P2, N=50, Recruiting, Sponsor: Gilead Sciences
Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2018 --> Aug 2017 Not yet recruiting --> Recruiting
- || lanraplenib (GS-9876) / Gilead, Galapagos, Kronos Bio
Trial primary completion date: Pharmacokinetics of Lanraplenib in Adults With Impaired Renal Function (clinicaltrials.gov) - May 22, 2017
P1, N=60, Recruiting, Sponsor: Gilead Sciences
Not yet recruiting --> Recruiting Trial primary completion date: Jul 2017 --> Dec 2017
- |||| lanraplenib (GS-9876) / Gilead, Galapagos, Kronos Bio, Velexbru (tirabrutinib) / Ono Pharma, Gilead, Jyseleca (filgotinib) / Galapagos, Gilead, SOBI
Enrollment open: Study to Assess Safety and Efficacy of Filgotinib, Lanraplenib and Tirabrutinib in Adults With Active Sjogren's Syndrome (clinicaltrials.gov) - May 8, 2017
P2, N=140, Recruiting, Sponsor: Gilead Sciences
Trial primary completion date: Jul 2017 --> Dec 2017 Not yet recruiting --> Recruiting
- | lanraplenib (GS-9876) / Gilead, Galapagos, Kronos Bio, Jyseleca (filgotinib) / Galapagos, Gilead, SOBI
New P2 trial: Study to Evaluate Safety and Efficacy of Filgotinib and Lanraplenib in Females With Moderately-to-Severely Active Cutaneous Lupus Erythematosus (CLE) (clinicaltrials.gov) - Apr 27, 2017
P2, N=50, Not yet recruiting, Sponsor: Gilead Sciences
- ||||| lanraplenib (GS-9876) / Gilead, Galapagos, Kronos Bio, Velexbru (tirabrutinib) / Ono Pharma, Gilead, Jyseleca (filgotinib) / Galapagos, Gilead, SOBI
New P2 trial: Study to Assess Safety and Efficacy of Filgotinib, Lanraplenib and Tirabrutinib in Adults With Active Sjogren's Syndrome (clinicaltrials.gov) - Apr 4, 2017
P2, N=140, Not yet recruiting, Sponsor: Gilead Sciences
- ||| lanraplenib (GS-9876) / Gilead, Galapagos, Kronos Bio
Enrollment open: Pharmacokinetics of Lanraplenib in Adults With Impaired Renal Function (clinicaltrials.gov) - Dec 14, 2016
P1, N=60, Recruiting, Sponsor: Gilead Sciences
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||| lanraplenib (GS-9876) / Gilead, Galapagos, Kronos Bio
New P1 trial: Pharmacokinetics of Lanraplenib in Adults With Impaired Renal Function (clinicaltrials.gov) - Nov 8, 2016
P1, N=60, Not yet recruiting, Sponsor: Gilead Sciences
- |||| lanraplenib (GS-9876) / Gilead, Galapagos, Kronos Bio
Enrollment open: Safety, Tolerability, and Efficacy of GS-9876 in Participants With Active Rheumatoid Arthritis on Background Therapy With Methotrexate (clinicaltrials.gov) - Oct 5, 2016
P2, N=80, Recruiting, Sponsor: Gilead Sciences
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||||| lanraplenib (GS-9876) / Gilead, Galapagos, Kronos Bio
New P2 trial: Safety, Tolerability, and Efficacy of GS-9876 in Participants With Active Rheumatoid Arthritis on Background Therapy With Methotrexate (clinicaltrials.gov) - Aug 30, 2016
P2, N=80, Not yet recruiting, Sponsor: Gilead Sciences